Edwards Lifesciences (EW) traded higher on Thursday, April 23, 2026, with the move aligning with a classic “earnings eve” setup: investors positioning ahead of the company’s expected after-hours quarterly release and conference call timing. Options and short-term traders frequently push shares in either direction on the day of a scheduled report, and EW is on the market’s calendar for an after-hours update today. (intellectia.ai)

Beyond near-term earnings positioning, Edwards has had multiple fundamental catalysts in focus. In late March, the company highlighted two-year TRISCEND II randomized trial results for its EVOQUE transcatheter tricuspid valve replacement system, pointing to improved outcomes including lower mortality in analyses accounting for crossover—an update that reinforced investor attention on the company’s TMTT pipeline and commercialization trajectory. (investing.com)

Separately, Medicare reimbursement expectations have been in the spotlight. CMS accepted a request tied to a national coverage determination review for TAVR, with a proposed decision memo due June 15, 2026 and a final coverage decision expected around September 2026—timing that keeps “access expansion” as a potential second-half catalyst for the core TAVR franchise. (massdevice.com)

With EW reporting after the close today, investors will likely key on management’s outlook for 2026 growth and the pace of adoption across structural heart segments, particularly TAVR demand trends and the ramp for newer therapies within the mitral and tricuspid portfolio. Any commentary that tightens the narrative around the Medicare TAVR coverage review timeline or shows continued traction for EVOQUE could extend the move, while cautious guidance could temper it. (massdevice.com)